Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
AbstractThe dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM), including the USA, Europe, and Japan. Alogliptin is efficacious both as monotherapy and as add-on/combination therapy with other commonly prescribed T2DM treatments, such as metformin and pioglitazone. Overall, alogliptin is well-tolerated in patients with T2DM, including older patients, those with renal and/or hepatic impairment, and those at high risk of cardiovascular events. There is a low risk of hypoglycemia, weight gain, acute pancreatitis, and gastrointestinal adverse events with alogliptin treatment, as demonstrated in long-term trials (lasting up to 4.5 years) and in a real-world setting. Additionally, alogliptin has a generally favorable or similar safety profile in comparison to other antidiabetic agents (metformin, thiazolidinediones, sulfonylureas, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, α-glucos idase inhibitors, and insulin). However, further evaluation would be required to determine the mechanism and effect of alogliptin on heart failure, bullous pemphigoid, and inflammatory bowel disease. Of note, due to the ethnic diversity in the epidemiology of T2DM, alogliptin has been shown to be mo re efficacious in Asian patients than in non-Asian patients with T2DM, but with a similar tolerability profile. These data indic...
Is the seated saline infusion test an accurate means of determining primary aldosteronism subtypes? How does it compare with other tests?Clinical Endocrinology
TYPE 2 diabetes is a chronic condition that requires a person to overhaul aspects of their lifestyle to keep rising blood sugar levels in check. Diet plays a decisive role in regulating blood sugar and warding off the threat of developing serious conditions and evidence is increasingly singling out certain items for their blood sugar-lowering benefits, including a certain fruit.
CONCLUSION: A thoughtful ileostomy is important so as to not sacrifice bowel in patients being prepared for redo ileal pouch surgery. Initial diversion with thoughtful ileostomy 6 months before redo ileal pouch construction also allows patients to be prepared for a major operation both physiologically and psychologically.
Background Diabetes mellitus predicts poorer outcomes in patients with acute coronary syndrome (ACS), but the magnitude of this association in patients at older ages remains controversial. Methods Data were extracted from the Codi Infart database. All consecutive patients with diagnosis of ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) between 2010 and 2015 were included. We assessed the impact of diabetes mellitus on 30-day and one-year mortality in patients aged less than and at least 75 years. Results A total of 12 792 cases were registered, of whom...
Conclusion: Sirolimus-eluting Stentys stent may represent a potential solution for specific coronary anatomies such as bifurcation, ectasic, or tapered vessels. Risk of stent thrombosis appears related to clinical presentation with STEMI and to anatomic features, stressing the importance of the use of intracoronary imaging for self-expandable stents implantation.
Conclusions DCB angioplasty for de novo small coronary lesions in the real-world environment in Japan is effective with acceptable 12-month outcomes.
Background We hypothesized that the transition from bare-metal stents (BMS) to newer generation drug-eluting stents (n-DES) in clinical practice may have reduced the risk also in patients with kidney dysfunction. Methods: Observational study in the national SWEDEHEART registry, that compared the 1-year risk of in-stent restenosis (RS) and stent thrombosis (ST) in all percutaneous coronary intervention treated patients(n = 92 994) during 2007–2013. Results: N-DES patients were younger than BMS, but had more often diabetes, previous myocardial infarction, previous revascularization and were more often treated w...
No abstract available
Date: Friday, 12 13, 2019; Speaker: Jonathan Epstein, M.D., William Wikoff Smith Professor/Exec. Vice Dean, University of Pennsylvania; Building: Building 6B; 4B429 4th floor library
A subanalysis of CREDENCE suggests that SGLT2 inhibitor use should be based on clinical benefit, not solely glycemic control, say researchers. Another study hints that these drugs up EPO levels.Medscape Medical News
More News: Actos | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Epidemiology | Fortamet | Gastroenterology | Heart | Heart Failure | Inflammatory Bowel Disease | Insulin | Japan Health | Metformin | Pancreatitis | Pemphigoid | Sodium